Eden Biodesign’s Second MHRA Audit is Successful

Eden Biodesign has completed a successful second audit by the UK Medicines and Healthcare Products Regulatory Agency (MHRA), European Medicines Agency (EMEA) to manufacture Investigational Medicinal Products (IMPs) at its facility in Liverpool, UK.

The three-day MHRA inspection took place in March 2009 and demonstrates that the company’s processes, facilities and quality systems meet cGMP standards, with no critical or major deficiencies found by the inspector.

“I am delighted that our world-class cGMP production facilities have passed their second audit,” said Dr. Crawford Brown, co-founder and chief executive officer of Eden Biodesign. “The inspection recognizes that we have a highly trained and knowledgeable team and appropriate and well-developed quality systems in place at Eden Biodesign. We have a growing track record with a global client base, and we deliver a full-service offering for the production of new medicines across all major biopharmaceutical production platforms.”